Last updated: September 29, 2025
Sponsor: Novartis Pharmaceuticals
Overall Status: Active - Not Recruiting
Phase
1
Condition
Red Blood Cell Disorders
Sickle Cell Disease
Treatment
OTQ923
OTQ923
Clinical Study ID
NCT06155500
CADPT03A12001
Ages 18-100 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patients must have received gene therapy treatment from the parent treatmentprotocol (CADPT03A12101).
Patients must provide informed consent prior to their entry into this study.
Exclusion
Exclusion Criteria:
- Completion of less than 1 year of safety follow-up in the treatment protocol (CADPT03A12101).
Study Design
Total Participants: 4
Treatment Group(s): 2
Primary Treatment: OTQ923
Phase: 1
Study Start date:
April 16, 2024
Estimated Completion Date:
January 11, 2039
Study Description
Connect with a study center
University of Chicago
Chicago 4887398, Illinois 4896861 60637
United StatesSite Not Available
Memorial Sloan Kettering Cancer Ctr
New York 5128581, New York 5128638 10065
United StatesSite Not Available
St Jude Childrens Rsrch Hospital
Memphis, Tennessee 38105-3678
United StatesSite Not Available
St Jude Childrens Research Hospital
Memphis 4641239, Tennessee 4662168 38105
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.